Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254773 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT01254773: Completed Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT01254773 is a Phase 2 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 146 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01254773, a Phase 2 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Interventions
- DRUG Experimental Bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01254773 record still lists
NCT01254773 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 1 intervention - of which Experimental Bapineuzumab is the first listed.
NCT01254773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01254773 about?
NCT01254773 is a clinical study titled "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease". This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
What is the current status of trial NCT01254773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2010-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01254773?
The interventions under investigation include: Experimental Bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT01254773?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01254773's enrollment target sits among peer trials
146 496th of 2000 higher than 1,503 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia